HK1218878A1 - 3-(咪唑并[1，2-b]哒嗪-3-基乙炔基)-4-甲基-n{4-[(4-甲基哌嗪-1-基)甲基]-3-(三氟甲基)苯基}苯甲酰胺和它的单盐酸盐的晶形 - Google Patents

3-(咪唑并[1，2-b]哒嗪-3-基乙炔基)-4-甲基-n{4-[(4-甲基哌嗪-1-基)甲基]-3-(三氟甲基)苯基}苯甲酰胺和它的单盐酸盐的晶形 Download PDF

Info

Publication number
HK1218878A1
HK1218878A1 HK16106954.3A HK16106954A HK1218878A1 HK 1218878 A1 HK1218878 A1 HK 1218878A1 HK 16106954 A HK16106954 A HK 16106954A HK 1218878 A1 HK1218878 A1 HK 1218878A1
Authority
HK
Hong Kong
Prior art keywords
methyl
crystalline form
mixture
total weight
imidazo
Prior art date
Application number
HK16106954.3A
Other languages
English (en)
Chinese (zh)
Inventor
Christopher K. Murray
Leonard W. Rozamus
John J. CHABER
Pradeep Sharma
Original Assignee
阿里亚德医药股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50929140&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1218878(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 阿里亚德医药股份有限公司 filed Critical 阿里亚德医药股份有限公司
Publication of HK1218878A1 publication Critical patent/HK1218878A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK16106954.3A 2012-12-12 2013-12-12 3-(咪唑并[1，2-b]哒嗪-3-基乙炔基)-4-甲基-n{4-[(4-甲基哌嗪-1-基)甲基]-3-(三氟甲基)苯基}苯甲酰胺和它的单盐酸盐的晶形 HK1218878A1 (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261736543P 2012-12-12 2012-12-12
US61/736,543 2012-12-12
US201261737007P 2012-12-13 2012-12-13
US61/737,007 2012-12-13
US201361788208P 2013-03-15 2013-03-15
US61/788,208 2013-03-15
PCT/US2013/074571 WO2014093579A2 (en) 2012-12-12 2013-12-12 Crystalline forms of 3-(imidazo[1,2-b] pyridazin-3-ylethynyl)-4-methyl-n-(4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)phenyl)benzamide and its mono hydrochloride salt

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
HK42023069906.8A Division HK40080449A (en) 2012-12-12 2016-06-16 Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt

Related Child Applications (1)

Application Number Title Priority Date Filing Date
HK42023069906.8A Addition HK40080449A (en) 2012-12-12 2016-06-16 Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt

Publications (1)

Publication Number Publication Date
HK1218878A1 true HK1218878A1 (zh) 2017-03-17

Family

ID=50929140

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16106954.3A HK1218878A1 (zh) 2012-12-12 2013-12-12 3-(咪唑并[1，2-b]哒嗪-3-基乙炔基)-4-甲基-n{4-[(4-甲基哌嗪-1-基)甲基]-3-(三氟甲基)苯基}苯甲酰胺和它的单盐酸盐的晶形

Country Status (9)

Country Link
US (9) US9493470B2 (enExample)
JP (5) JP6447508B2 (enExample)
CN (2) CN115043843A (enExample)
CA (3) CA3022250A1 (enExample)
CL (1) CL2015001643A1 (enExample)
HK (1) HK1218878A1 (enExample)
MX (11) MX359147B (enExample)
NZ (1) NZ709648A (enExample)
WO (2) WO2014093583A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2495016B1 (en) 2005-12-23 2019-10-16 Ariad Pharmaceuticals, Inc. Bicyclic Heteroaryl Compounds
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
CA3022250A1 (en) 2012-12-12 2014-06-12 Ariad Pharmaceuticals, Inc. Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride
AU2014286047B2 (en) 2013-07-04 2018-02-08 Sandoz Ag Crystalline forms of ponatinib hydrochloride
CN104496994B (zh) * 2014-01-06 2016-12-07 广东东阳光药业有限公司 一种炔类杂芳基化合物的新晶型
KR20190092538A (ko) * 2016-12-15 2019-08-07 어리어드 파마슈티칼스, 인코포레이티드 C-kit 억제제로서의 벤즈이미다졸 화합물
US10221184B2 (en) 2017-01-20 2019-03-05 Apicore Us Llc Polymorphs of ponatinib hydrochloride
US11072620B2 (en) 2017-06-20 2021-07-27 Apotex Inc. Crystalline forms of Ponatinib hydrochloride
PT3774844T (pt) * 2018-04-02 2023-03-28 Stealth Biotherapeutics Inc Dipeptídeos cristalinos úteis na síntese de elamipretida
EP3781568A1 (en) 2018-06-22 2021-02-24 Johnson Matthey Public Limited Company Form of ponatinib
AU2019371454A1 (en) 2018-11-01 2021-05-27 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
WO2020223235A1 (en) 2019-04-29 2020-11-05 Incyte Corporation Mini-tablet dosage forms of ponatinib
CN111004240B (zh) * 2019-12-13 2020-12-01 山东铂源药业有限公司 一种泊那替尼中间体3-乙炔基咪唑并[1,2-b]哒嗪的合成方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5099067A (en) 1988-08-05 1992-03-24 Northwestern University Use of ammonium formate as a hydrogen transfer reagent for reduction of chiral nitro compounds with retention of configuration
AU1465301A (en) * 1999-11-08 2001-06-06 Schering Corporation Process for preparing n-(4-hydroxy-phenyl)-n'-(4'-aminophenyl)-piperazine
HN2001000008A (es) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
DE10021246A1 (de) 2000-04-25 2001-10-31 Schering Ag Substituierte Benzoesäureamide und deren Verwendung als Arzneimittel
IL159811A0 (en) 2001-07-13 2004-06-20 Neurogen Corp Heteroaryl substituted fused bicyclic heteroaryl compounds as gabaa receptor ligands
AR041992A1 (es) 2002-11-06 2005-06-08 Smithkline Beecham Corp Compuesto de piridinil benzoheterociclico, composicion farmaceutica que lo comprende y su uso para prepararla
GB0230089D0 (en) 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
AR047496A1 (es) 2003-11-28 2006-01-25 Novartis Ag Derivados de diaril-urea en el tratamiento de enfermedades dependientes de la quinasa de proteina
JP2007513134A (ja) * 2003-12-05 2007-05-24 ビオヴィトルム・アクチボラゲット ２−置換アデノシンの改善された合成
DE602004018193D1 (de) 2003-12-24 2009-01-15 Astrazeneca Ab Pyrimidine mit tie2 (tek) aktivität
JP2007517006A (ja) 2003-12-24 2007-06-28 アストラゼネカ アクチボラグ Ｔｉｅ２（ｔｅｋ）活性のあるピリミジン
BRPI0508790A (pt) 2004-04-07 2007-09-04 Applied Research Systems ácido carboxìlicos, uso de um ácido carboxìlico, composto farmacêutico, método de preparação de ácido carboxìlico e composto intermediário
CA2573185A1 (en) 2004-07-14 2006-02-23 Ptc Therapeutics, Inc. Methods for treating hepatitis c
US7776869B2 (en) 2004-10-18 2010-08-17 Amgen Inc. Heteroaryl-substituted alkyne compounds and method of use
GB0502418D0 (en) 2005-02-05 2005-03-16 Astrazeneca Ab Compounds
EP1893605A2 (en) 2005-03-31 2008-03-05 AstraZeneca AB Saminopyrimidine derivates with tie2 inhibiting activity
JP2009502734A (ja) 2005-07-29 2009-01-29 アステラス製薬株式会社 Ｌｃｋ阻害剤としての縮合複素環
WO2007021937A2 (en) 2005-08-11 2007-02-22 Ariad Pharmaceuticals, Inc. Unsaturated heterocyclic derivatives
EP2495016B1 (en) 2005-12-23 2019-10-16 Ariad Pharmaceuticals, Inc. Bicyclic Heteroaryl Compounds
SI1973545T1 (sl) * 2005-12-23 2013-04-30 Ariad Pharmaceuticals, Inc. Spojine bicikličnega heteroarila
BRPI0710331A2 (pt) 2006-05-08 2012-03-20 Ariad Pharmaceuticals, Inc Compostos heteroarila monocíclicos para tratamento de câncer e composição
MX2008014289A (es) 2006-05-08 2008-11-26 Ariad Pharma Inc Compuestos heteroarilicos acetilenicos.
EP2107054A1 (en) 2008-04-01 2009-10-07 Università Degli Studi Di Milano - Bicocca Antiproliferative compounds and therapeutic uses thereof
US20100273772A1 (en) 2009-04-23 2010-10-28 Wyeth Llc Bisaryl Alkynylamides as Negative Allosteric Modulators of Metabotropic Glutamate Receptor 5 (MGLUR5)
US8329724B2 (en) * 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
EA201290255A1 (ru) * 2009-10-30 2013-04-30 Ариад Фармасьютикалз, Инк. Способы и композиции для лечения рака
CA2832483A1 (en) 2011-04-07 2012-10-11 Ariad Pharmaceuticals, Inc. Methods and compositions for treating neurodegenerative diseases
MX2013011589A (es) 2011-04-07 2013-12-16 Ariad Pharma Inc Metodos y composiciones para tratar enfermedad de parkinson.
EP2841062A4 (en) 2012-04-25 2015-11-25 Ariad Pharma Inc METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASES MEDIATED BY RAF KINASE
CA3022250A1 (en) 2012-12-12 2014-06-12 Ariad Pharmaceuticals, Inc. Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride

Also Published As

Publication number Publication date
US20210340149A1 (en) 2021-11-04
US20210277011A1 (en) 2021-09-09
CN115043843A (zh) 2022-09-13
MX2021002261A (es) 2021-05-27
MX2015007578A (es) 2016-03-21
CA3022250A1 (en) 2014-06-12
WO2014093579A2 (en) 2014-06-19
MX391445B (es) 2025-03-21
JP2016503010A (ja) 2016-02-01
CA3167093A1 (en) 2014-06-12
WO2014093579A3 (en) 2014-07-10
CL2015001643A1 (es) 2015-10-02
US20240083902A1 (en) 2024-03-14
MX359147B (es) 2018-09-17
JP7042175B2 (ja) 2022-03-25
US10662197B2 (en) 2020-05-26
US20210277012A1 (en) 2021-09-09
US11384086B2 (en) 2022-07-12
NZ709648A (en) 2020-05-29
MX2021002255A (es) 2021-05-27
MX2021002254A (es) 2021-05-27
US9493470B2 (en) 2016-11-15
JP2023179498A (ja) 2023-12-19
WO2014093583A2 (en) 2014-06-19
JP2026010061A (ja) 2026-01-21
CN105188701A (zh) 2015-12-23
US20170190707A1 (en) 2017-07-06
US20210024527A1 (en) 2021-01-28
MX2021002253A (es) 2021-05-27
US11192896B2 (en) 2021-12-07
MX2021002259A (es) 2021-05-27
US10125136B2 (en) 2018-11-13
US11192897B2 (en) 2021-12-07
CA2815506C (en) 2018-12-11
JP2022037122A (ja) 2022-03-08
CA2815506A1 (en) 2014-06-12
MX2021002258A (es) 2021-05-27
MX2021002257A (es) 2021-05-27
WO2014093583A3 (en) 2014-08-07
JP2018168191A (ja) 2018-11-01
US20190169196A1 (en) 2019-06-06
JP7352841B2 (ja) 2023-09-29
JP6447508B2 (ja) 2019-01-09
US20210277010A1 (en) 2021-09-09
US20150315194A1 (en) 2015-11-05
US11279705B2 (en) 2022-03-22
US11192895B2 (en) 2021-12-07
MX2021002264A (es) 2021-05-27
MX2021002256A (es) 2021-05-27

Similar Documents

Publication Publication Date Title
JP7352841B2 (ja) ３－（イミダゾ［１，２－ｂ］ピリダジン－３－イルエチニル）－４－メチル－Ｎ－｛４－［（４－メチルピペラジン－１－イル）メチル］－３－（トリフルオロメチル）フェニル｝ベンズアミドおよびその一塩酸塩の結晶形
HK40080449A (en) Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt
AU2023219845B2 (en) Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N- {4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride
JP2022553718A (ja) Ｇａｂａａ陽性アロステリック調節因子化合物、作成方法、およびその使用
WO2013170241A1 (en) Polymorphs of 7-(tert-butyl-d9)-3-(2,5-difluorophenyl)-6-((1-methyl-1h-1,2,4-triazol-5-yl)methoxy)-[1,2,4]triazolol[4,3b]pyridazine